Novo’s Oral Diabetes Drug Hits Heart-Safety Goal in Study

Novo Nordisk A/S’s tablet version of its Ozempic injection for diabetes hit a heart-safety goal in a study that compared it with standard treatment alone.

Patients who received oral semaglutide along with the standard regimen suffered 21 percent fewer major heart complications than those who got a placebo, the Danish drugmaker said in a statement. While that wasn’t enough to show that the drug was safer than standard care, it hit the goal of showing it’s at least as safe, and also demonstrated significant reductions in cardiovascular-related and overall deaths.

Novo has been working to follow up on Ozempic, its ...